Calidi Biotherapeutics, Inc.
NYSE · CIK 0001855485 · Fiscal year end 1231
Latest reported period: Latest published period
Operating Income
$-4.2M
Net Income
$-4.1M
Eps Basic
-0.43
Recent financials
| Metric | Current | Prior | Change |
|---|---|---|---|
| Operating Income | $-4.2M | - | - |
| Net Income | $-4.1M | - | - |
| Eps Basic | -0.43 | - | - |
| Eps Diluted | -0.43 | - | - |
| Total Assets | $9.6M | - | - |
| Total Liabilities | $4.7M | - | - |
| Shareholders Equity | $4.9M | - | - |
| Operating Cash Flow | $-4.1M | - | - |
Latest filings
| Form | Company | Filed | Accession |
|---|---|---|---|
| 10-Q | Calidi Biotherapeutics, Inc. | 2026-05-14 | 0001493152-26-023140 |
| 10-K | Calidi Biotherapeutics, Inc. | 2026-03-27 | 0001493152-26-013242 |
| 4 | Calidi Biotherapeutics, Inc. | 2025-12-16 | 0001493152-25-028030 |
| 10-Q | Calidi Biotherapeutics, Inc. | 2025-11-13 | 0001493152-25-022372 |
| 4 | Calidi Biotherapeutics, Inc. | 2025-08-25 | 0001641172-25-025448 |
| 4 | Calidi Biotherapeutics, Inc. | 2025-08-25 | 0001641172-25-025447 |
| 4 | Calidi Biotherapeutics, Inc. | 2025-08-25 | 0001641172-25-025446 |
| 4 | Calidi Biotherapeutics, Inc. | 2025-08-25 | 0001641172-25-025445 |
| 10-Q | Calidi Biotherapeutics, Inc. | 2025-08-08 | 0001641172-25-022797 |